The Patient Global Evaluation scores improved in both groups but showed greater improvement in Group A, while the Physician Global Evaluation improved significantly only in Group A. At the end of the 30-day treatment period, there were reductions in the pain scale scores in both groups, however there was a significantly larger reduction in the scores of the Group A patients. The safety evaluation took into account physical evaluations and laboratory tests performed at each visit to the study center as well as the incidence and severity of adverse events. Efficacy measures evaluated global patient condition from the perspective of the subject and the investigating physician pain - measured by a visual-analog scale and functionality, using a patient-response questionnaire. The subjects received a thrice-daily oral treatment regimen of either the combination treatment (Group A: total daily dose of 9mg UTP, 15mg CMP, 6 mg hydroxocobalamin) or vitamin B12 alone (Group B: total daily dose of 6 mg hydroxocobalamin). Following informed consent, 80 patients were randomized to a 30 day treatment period. The use of a combination of uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxocobalamin was evaluated in a double-blind, randomized study in the treatment of neuralgia due to degenerative orthopedic alterations with neural compression. Goldberg H, Scussel Jr, AB, Cohen JC, Rzetelna H, Mezitis SGE, Nunes FP, Ozeri D, Daher JPL, Nunes CP, Oliveira L, Geller M Neural compression-induced neuralgias: clinical evaluation of the effect of nucleotides associated with vitamin B12 Links Export Central Citation

Neural compression-induced neuralgias: clinical evaluation of the effect of nucleotides associated with vitamin B12В .Cochrane Database of Systematic Reviews.

Neural compression-induced neuralgias: clinical evaluation of the effect of nucleotides associated with vitamin B12В .

Nucleo forte capsules